±«Óãtv

A Dal research spinoff company

When the idea that became Adaptiiv was in its infancy, OCIE provided early and essential support in the form of resources to establish proof-of-concept, to define intellectual property, and to locate partners for commercialization. From the point-of-view of the licensee, OCIE was both flexible and collaborative, allowing the spin-out to leverage valuable IP and to move forward rapidly, without introducing barriers.

— Dr. James Robar, Co-Founder & Chief Science Officer, Adaptiiv

Summary
Born of radiation oncology research in ±«Óãtv’s Department of Radiation Technology, is a healthcare technology start-up specializing in software that helps clinicians improve radiation treatment accuracy and patient care.

To ensure cancer patients are receiving tailored and precise dosing during their radiation treatment, Adaptiiv has developed software that integrates with clinician treatment planning systems and allows for the 3D printing of personalized accessories for external beam radiotherapy or high dose-rate brachytherapy. Adaptiiv solutions improve the quality, efficiency and patient experience during radiation therapy.

Adaptiiv’s innovative technology is in all major markets worldwide and will be deployed in the Nova Scotia Health Authority’s clinical workflow.

The OCIE team supported the earliest stages of Adaptiiv’s growth through IP analysis, technology patenting, and finding funding support.

To learn more about Adaptiiv, visit 

Inventor & Co-Founder

• 
  Professor, Departments of Radiation Oncology and Physics & Atmospheric Science (±«Óãtv)
  Chief, Department of Medical Physics (Nova Scotia Health)